Tafalgie Therapeutics
Latest round
- Series A
Last raised
- Feb 2025
Total raised
- $5M
Investors
- 2
About Tafalgie Therapeutics
Founded in 2020 by co-founders Aziz MOQRICH, Stéphane GAILLARD, Eric SCHETTINI, and Laurent LABATUT and based in France, Tafalgie Therapeutics SA is a developer of drugs that can treat pain at all levels without the major drawbacks of existing painkillers. Tafalgie Therapeutics is focused on the research and development of advanced-generation analgesic peptides. The medications target a specific protein (TAFA4) involved in pain signaling and prevent both acute and chronic pain without addiction or tolerance issues. These medications are still under development and not yet available to the public. The company’s product pipeline includes targeted therapeutics for various types of pain, including post-operative pain, rare diseases, and acute and chronic pain. The lead compounds are in different stages of development, from preclinical research to Phase 2 clinical trials.
Who invested in Tafalgie Therapeutics
2 investors across 1 round
See all investors in Tafalgie Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 27, 2025
Amount
$5M
Investors
Questions about Tafalgie Therapeutics
Who invested in Tafalgie Therapeutics?
Tafalgie Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tafalgie Therapeutics raised?
Tafalgie Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Tafalgie Therapeutics last raise money?
Tafalgie Therapeutics's most recent round on record is a Series A, in Feb 2025.
What does Tafalgie Therapeutics do?
Founded in 2020 by co-founders Aziz MOQRICH, Stéphane GAILLARD, Eric SCHETTINI, and Laurent LABATUT and based in France, Tafalgie Therapeutics SA is a developer of drugs that can treat pain at all levels without the major drawbacks of existing painkillers.
Where is Tafalgie Therapeutics headquartered?
Tafalgie Therapeutics is headquartered in France.
Which VCs invest in companies like Tafalgie Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Tafalgie Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Tafalgie Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.